参考文献/References:
[1] Monticone S,D'Ascenzo F,Moretti C,et al.Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension:a systematic review and meta-analysis[J].Lancet Diabetes Endocrinol,2018,6(1):41-50.DOI:10.1016/S2213-8587(17)30319-4.
[2] Scholl UI,Stölting G,Schewe J,et al.CLCN2 chloride channel mutations in familial hyperaldosteronism type II[J].Nat Genet,2018,50(3):349-354.DOI:10.1038/s41588-018-0048-5.
[3] Fernandes-Rosa FL,Williams TA,Riester A,et al.Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma[J].Hypertension,2014,64(2):354-361.DOI:10.1161/HYPERTENSIONAHA.114.03419.
[4] Kitamoto T,Suematsu S,Yamazaki Y,et al.Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations[J].J Clin Endocrinol Metab,2016,101(2):494-503.DOI:10.1210/jc.2015-3284.
[5] Teo AE,Garg S,Shaikh LH,et al.Pregnancy,primary aldosteronism,and adrenal CTNNB1 mutations[J].N Engl J Med,2015,373(15):1429-1436.DOI:10.1056/NEJMoa1504869.
[6] Rhayem Y,Perez-Rivas LG,Dietz A,et al.PRKACA somatic mutations are rare findings in aldosterone-producing adenomas[J].J Clin Endocrinol Metab,2016,101(8):3010-3017.DOI:10.1210/jc.2016-1700.
[7] Young WF.Diagnosis and treatment of primary aldosteronism:practical clinical perspectives[J].J Intern Med,2019,285(2):126-148.DOI:10.1111/joim.12831.
[8] Funder JW,Carey RM,Mantero F,et al.The management of primary aldosteronism:case detection,diagnosis,and treatment:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.DOI:10.1210/jc.2015-4061.
[9] Scholl UI,Nelson-Williams C,Yue P,et al.Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5[J].Proc Natl Acad Sci U S A,2012,109(7):2533-2538.DOI:10.1073/pnas.1121407109.
[10] Monticone S,Hattangady NG,Penton D,et al.A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type Ⅲ[J].J Clin Endocrinol Metab,2013,98(11):1861-1865.DOI:10.1210/jc.2013-2428.
[11] Tong A,Liu G,Wang F,et al.A novel phenotype of familial hyperaldosteronism type Ⅲ:concurrence of aldosteronism and cushing's syndrome[J].J Clin Endocrinol Metab,2016,101(11):4290-4297.DOI:10.1210/jc.2016-1504.
[12] Daniil G,Fernandes-Rosa FL,Chemin J,et al.CACNA1H mutations are associated with different forms of primary aldosteronism[J].EBioMedicine,2016,13:225-236.DOI:10.1016/j.ebiom.2016.10.002.
[13] Reimer EN,Walenda G,Seidel E,et al.CACNA1H(M1549V)mutant calcium channel causes autonomous aldosterone production in HAC15 cells and is inhibited by mibefradil[J].Endocrinology,2016,157(8):3016-3022.DOI:10.1210/en.2016-1170.
[14] Wulczyn K,Perez-Reyes E,Nussbaum RL,et al.Primary aldosteronism associated with a germline variant in CACNA1H[J].BMJ Case Rep,2019,12(5):e229031.DOI:10.1136/bcr-2018-229031.
[15] Ortner NJ,Kaserer T,Copeland JN,et al.De novo CACAN1D Ca2+ channelopathies:clinical phenotypes and molecular mechanism[J].Pflugers Arch,2020,472(7):755-773.DOI:10.1007/s00424-020-02418-w.
[16] Lenzini L,Rossitto G,Maiolino G,et al.A meta-analysis of somatic KCNJ5 K(+)channel mutations in 1636 patients with an aldosterone-producing adenoma[J].J Clin Endocrinol Metab,2015,100(8):E1089-E1095.DOI:10.1210/jc.2015-2149.
[17] Williams TA,Peitzsch M,Dietz AS,et al.Genotype-specific steroid profiles associated with aldosterone-producing adenomas[J].Hypertension,2016,67(1):139-145.DOI:10.1161/HYPERTENSIONAHA.115.06186.
[18] Dutta RK,Arnesen T,Heie A,et al.A somatic mutation in CLCN2 identified in a sporadic aldosterone-producing adenoma[J].Eur J Endocrinol,2019,181(5):K37-K41.DOI:10.1530/EJE-19-0377.
[19] Rege J,Nanba K,Blinder AR,et al.Identification of somatic mutations in CLCN2 in aldosterone-producing adenomas[J].J Endocr Soc,2020,4(10):bvaa123.DOI:10.1210/jendso/bvaa123.
[20] Tseng CS,Peng KY,Wang SM,et al.A novel somatic mutation of CACNA1H p.V1937M in unilateral primary hyperaldosteronism[J].Front Endocrinol(Lausanne),2022,13:816476.DOI:10.3389/fendo.2022.816476.
[21] Nanba K,Blinder AR,Rege J,et al.Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma[J].Hypertension,2020,75(3):645-649.DOI:10.1161/HYPERTENSIONAHA.119.14349.
[22] Zhou J,Azizan EAB,Cabrera CP,et al.Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty,pregnancy or menopause[J].Nature Genetics,2021,53(9):1360-1372.DOI:10.1038/s41588-021-00906-y.
[23] Parthasarathy HK,Ménard J,White WB,et al.A double-blind,randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism[J].J Hypertens,2011,29(5):980-990.DOI:10.1097/HJH.0b013e3283455ca5.
[24] Georgianos PI,Agarwal R.Mineralocorticoid receptor antagonism in chronic kidney disease[J].Kidney Int Rep,2021,6(9):2281-2291.DOI:10.1016/j.ekir.2021.05.027.
[25] Tauber P,Penton D,Stindl J,et al.Pharmacology and pathophysiology of mutated KCNJ5 found in adrenal aldosterone-producing adenomas[J].Endocrinology,2014,155(4):1353-1362.DOI:10.1210/en.2013-1944.
[26] Scholl UI,Abriola L,Zhang C,et al.Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma[J].J Clin Invest,2017,127(7):2739-2750.DOI:10.1172/JCI91733.
[27] Zhang SL,Gao JW,Guo Y,et al.Associations between metabolic profiles and trget-organ damage in Chinese individuals with primary aldosteronism[J].Front Endocrinol(Lausanne),2020,11:547356.DOI:10.3389/fendo.2020.547356.
[28] Forzano I,Mone P,Varzideh F,et al.The selective aldosterone synthase inhibitor baxdrostat significantly lowers blood pressure in patients with resistant hypertension[J].Front Endocrinol(Lausanne),2022,13:1097968.DOI:10.3389/fendo.2022.1097968.
相似文献/References:
[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(03):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
[2]周庆菊,李蓉.MODY2的认识及诊疗进展[J].国际内分泌代谢杂志,2016,36(03):180.[doi:10.3760/cma.j.issn.1673-4157.2016.03.09]
Zhou Qingju,Li Rong..The cognition, diagnosis and treatment of MODY2[J].International Journal of Endocrinology and Metabolism,2016,36(03):180.[doi:10.3760/cma.j.issn.1673-4157.2016.03.09]
[3]曲玉清,王安平,王先令,等.单基因突变致激素不敏感综合征的研究进展[J].国际内分泌代谢杂志,2017,37(01):59.[doi:10.3760/cma.j.issn.1673-4157.2017.01.17]
Qu Yuqing,Wang Anping,Wang Xianling,et al.Research progress in hormone insensitivity syndrome caused by single gene mutation[J].International Journal of Endocrinology and Metabolism,2017,37(03):59.[doi:10.3760/cma.j.issn.1673-4157.2017.01.17]
[4]郭曼丽,李伟,马绍刚,等.甲状腺过氧化物酶基因c.2268dupT突变与甲状腺结节的相关性研究[J].国际内分泌代谢杂志,2017,37(04):232.
Guo Manli*,Li Wei,Ma Shaogang,et al.Relationship between c.2268dupT mutation in thyroid peroxidase gene and thyroid nodules[J].International Journal of Endocrinology and Metabolism,2017,37(03):232.
[5]游晶玉,罗飞宏.单基因糖尿病的研究进展[J].国际内分泌代谢杂志,2017,37(04):266.
You Jingyu,Luo Feihong..Recent progress of monogenic diabetes[J].International Journal of Endocrinology and Metabolism,2017,37(03):266.
[6]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(03):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
[7]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(03):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[8]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(03):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
[9]彭雅洁,朱文娇,施缘萍,等.DNA损伤修复和遗传缺陷导致的脂肪分化异常及胰岛素抵抗的研究进展[J].国际内分泌代谢杂志,2022,42(03):219.[doi:10.3760/cma.j.cn121383-20210120-01056]
Peng Yajie,Zhu Wenjiao,Shi Yuanping,et al.Abnormal adipose differentiation and insulin resistance caused by DNA damage repair and genetic defects[J].International Journal of Endocrinology and Metabolism,2022,42(03):219.[doi:10.3760/cma.j.cn121383-20210120-01056]
[10]中华医学会内分泌学分会内分泌罕见病学组.葡萄糖激酶基因突变导致的单基因糖尿病诊治专家共识[J].国际内分泌代谢杂志,2022,42(03):236.[doi:10.3760/cma.j.cn121383-20220107-01010]
Study Group of Endocrinology Rare Diseases,Chinese Society of Endocrinology.Diagnosis and management of monogenic diabetes caused by glucokinase gene mutations[J].International Journal of Endocrinology and Metabolism,2022,42(03):236.[doi:10.3760/cma.j.cn121383-20220107-01010]
[11]王慧萍,童安莉.原发性醛固酮增多症相关的基因突变研究进展[J].国际内分泌代谢杂志,2021,41(02):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
Wang Huiping,Tong Anli..Research progress on gene mutation related primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(03):87.[doi:10.3760/cma.j.cn121383-20200706-07013]